The Proper Use of 47-mm Flat Disc Filters in Filter Sizing Studies - Why staining is crucial in flow decay studies. - BioPharm International

ADVERTISEMENT

The Proper Use of 47-mm Flat Disc Filters in Filter Sizing Studies
Why staining is crucial in flow decay studies.


BioPharm International
Volume 22, Issue 9

SUMMARY

The ultimate goal of the filter sizing exercise is to quantify the effective filter area (EFA) needed to filter an entire production batch over a set time frame. Such testing typically is done using a flat disc with a diameter of 47-mm. The proper implementation of the flow decline method of assessing EFA requirements necessitates knowing the precise EFA of the model filter, which can be measured using staining techniques.

A filter-sizing study using a 47-mm flat disc is intended as indicator trial, which is preliminary to a more meaningful verification trial, or even to a more cogent assurance trial. The latter will require filter models characterized by a pleated membrane design. The EFA assessment of the pleated filter models can be performed with confidence. This will result in dependable projections of the EFA required for the batch processing filters.

Maik W. Jornitz is the group vice president of marketing & product management, filtration and fermentation technologies, and Wayne Garafola is an application specialist, both at Sartorius Stedim Biotech, Bohemia, NY, 631.870.8463,
Theodore H. Meltzer is the principal at Capitola Consulting Co., Bethesda, MD.

REFERENCES

1. Jornitz MW, Soelkner PG, Meltzer TH. Modern sterile filtration—the economics. PharmTech Eur. 2003;15(6)29–33.

2. Priebe PM, Jornitz MW, Meltzer TH. Making an informed membrane filter choice. BioProcess Int. 2003;1(10)64–6.

3. Parenteral Drug Association. Technical report 26: Liquid sterilizing filters. Bethesda, MD: PDA; 2008.

4. Meltzer TH, Jornitz MW. Pharmaceutical filtration—The management of organism removal. PDA, Bethesda, MD: PDA and River Grove, IL: DHI Publishing LLC; 2006.

5. Jornitz MW, Meltzer TH. Comparing flow rates of microporous membranes. Eur J Parenteral Pharm Sci. 2009:14(1)19–23.

6. Jornitz MW, Meltzer TH. Filtration and purification in the biopharmaceutical industry. New York, NY: Informa; 2008

7. Jornitz MW, Meltzer TH, Bromm H, Priebe PM. Testing for the optimal filter membrane. Gen Eng News. 2004;24(13)50–51.

8. Jornitz MW, Meltzer TH, Bromm H, Priebe PM. Choosing the appropriate membrane filter—test requirements. PDA J Pharm Sci Technol. 2005 Mar–Apr;59(2)96–101.

9. Jornitz MW. Filter construction and design. In: MW Jornitz, editor. Sterile Filtration. Berlin, Heidelberg: Springer Verlag; 2006. p. 105–124.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here